Eribulin Mesylate (CAS: 441045-17-6): Potent Microtubule-Targeting Agent for Cancer Therapy and ADCs
Eribulin Mesylate is a powerful synthetic analog of halichondrin B, known for its ability to target microtubules and disrupt cancer cell growth. It binds to tubulin, inhibiting microtubule formation, which leads to cell cycle arrest and apoptosis. With high specificity and unique action, Eribulin plays a crucial role in cancer therapy and bioconjugation.
Key Features and Mechanism
- Microtubule Inhibition: Eribulin stops microtubule growth, causing mitotic arrest and triggering cancer cell death.
- Specific Tubulin Binding: It uniquely binds to tubulin, setting it apart from other microtubule inhibitors.
Applications in Cancer Treatment
- FDA-Approved Uses: Approved for metastatic breast cancer and advanced liposarcoma, Eribulin improves survival in heavily pre-treated patients.
- ADC and Bioconjugation Potential: Eribulin links with antibodies in ADCs to target cancer cells precisely, enhancing efficacy and reducing side effects.
Eribulin in ADCs and Bioconjugation
- ADCs:
- Targeted Cancer Killing: Eribulin conjugated to antibodies precisely delivers the drug to cancer cells, minimizing toxicity.
- Enhanced Cancer Therapy: ADCs with Eribulin show increased effectiveness, particularly in resistant cancers.
- Bioconjugation:
- Versatile Linking: Easily conjugates with antibodies, peptides, and other molecules for customized treatments.
- Active in Research: Studied extensively for precision cancer therapies, Eribulin bioconjugates offer promising results.
Research and Future Potential
- Expanding Indications: Ongoing studies aim to broaden Eribulin’s use in other cancers and enhance its therapeutic effects.
- Combination Therapies: Research focuses on optimizing Eribulin for combination with other cancer treatments.
Handling and Safety
- Cytotoxicity: Handle Eribulin with caution due to its high potency. Follow safety protocols.
- Storage: Store properly to maintain effectiveness.
Eribulin Mesylate remains a valuable tool in cancer treatment, thanks to its unique mechanism and adaptability in ADCs and bioconjugation. It continues to drive advancements in targeted cancer therapies, offering new hope for patients with difficult-to-treat cancers.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
